Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference

Rhea-AI Summary

Dermata Therapeutics (NASDAQ:DRMA), a clinical-stage biotechnology company, will participate in the 2022 Maxim Group Virtual Growth Conference from March 28-30, 2022. CEO Gerry Proehl is set to present a fireside chat on March 28 at 12:00 p.m. PT. Dermata specializes in treating medical and aesthetic skin conditions, with its lead product candidate, DMT310, targeting acne, psoriasis, and rosacea. The conference will be hosted live on M-Vest, allowing attendees to engage directly with company executives.

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March 28-30, 2022. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer, will participate in a fireside chat on Monday, March 28, at 12:00 p.m. PT / 3:00 p.m. ET.

This conference will be live on M-Vest. To view, Click Here to Reserve your seat.

About Dermata

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is in clinical development for the topical treatment of acne, psoriasis, and rosacea. Dermata's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: the potential development and commercialization of product candidates; the ability of the Company's product candidates to achieve applicable endpoints in clinical trials; whether the results of the Company's product candidates will lead to future product development; and whether the Company will have the ability to obtain adequate funding for future development of its product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Investors:

Sean Proehl
Senior Director, Legal and Business Development
info@dermatarx.com

SOURCE: Dermata Therapeutics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/694448/Dermata-Therapeutics-to-Participate-in-the-2022-Maxim-Group-Virtual-Growth-Conference

FAQ

When is Dermata participating in the Maxim Group Virtual Growth Conference?

Dermata Therapeutics will participate in the Maxim Group Virtual Growth Conference from March 28-30, 2022.

Who will represent Dermata at the conference?

CEO Gerry Proehl will participate in a fireside chat during the conference on March 28 at 12:00 p.m. PT.

What is Dermata Therapeutics focusing on?

Dermata Therapeutics focuses on the treatment of medical and aesthetic skin conditions.

What is the lead product candidate of Dermata?

The lead product candidate of Dermata is DMT310, which is in clinical development for treating acne, psoriasis, and rosacea.

Where can I watch the conference live?

The conference can be watched live on M-Vest, and attendees can reserve their seats.